Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of HRG2010 versus sustained-release carbidopa/levodopa in Parkinson's disease with motor fluctuations
CTR20231044Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HRG2010(II) in Parkinson's disease (PD), sponsored by Hengrui Therapeutics. Started May 2023; status: completed.
02
Drugs
HRG2010(II)
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20231044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231044.